Form 4: Redmile Group Increases Stake in IGM Biosciences Through Director Compensation

Redmile Group, LLC, a 10% owner and director of IGM Biosciences, Inc., acquired 828 shares of common stock through a restricted stock unit grant as part of director compensation.

Summary

• Redmile Group, LLC, a 10% owner and director of IGM Biosciences, Inc. (IGMS), reported an acquisition of 828 shares of common stock.
• The acquisition occurred on June 30, 2025, and was in the form of fully vested restricted stock units.
• These units represent a quarterly retainer paid to Mr. Michael Lee, a managing director of Redmile Group and a member of IGM Biosciences' Board of Directors, under the Issuer's Outside Director Compensation Policy.
• Mr. Lee holds these securities as a nominee for Redmile, assigning all economic, pecuniary, and voting rights to Redmile.
• Following this transaction, Redmile Group's beneficial ownership stands at 2,964,843 shares of IGM Biosciences common stock.
• Jeremy Green, as the principal of Redmile, is also deemed a reporting person.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing detailing director compensation in the form of restricted stock units. It does not contain information that would significantly alter the company's financial outlook or strategic position, thus indicating a neutral sentiment.

Positives

• The transaction reflects a routine compensation mechanism for outside directors, indicating adherence to established corporate governance policies.
• The acquisition of shares by a significant institutional investor (Redmile Group) and its principal (Jeremy Green) could be seen as a minor positive signal of continued alignment with the company's interests, even if it is compensation-driven.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• These securities were granted to Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the Board of Directors of the Issuer.
• Pursuant to the policies of Redmile, Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile.
• Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile (collectively with Redmile, the "Reporting Persons").
• The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• Michael Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

Industry Context

This Form 4 filing is a routine disclosure of insider stock ownership changes, specifically related to director compensation. It does not provide broader industry context or trends, but it is common practice for public companies, particularly in the biotechnology sector like IGM Biosciences, to compensate directors with equity.

Corporate Governance

Related Party Transactions

• The grant of 828 restricted stock units to Mr. Michael Lee, a director and managing director of Redmile Group (a 10% owner), constitutes a related party transaction as it involves compensation to an individual affiliated with a significant shareholder and board member.

Stakeholder Impact

• Shareholders: Provides transparency on director compensation and the beneficial ownership structure of a significant institutional investor.
• Management/Board: Confirms the compensation structure for outside directors and clarifies reporting responsibilities for affiliated entities.

Key Dates

Keywords

IGM Biosciences, IGMS, Redmile Group, Jeremy Green, Michael Lee, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Director Compensation, Biotechnology, Healthcare Investment